Major salivary gland tumors: treatment results and prognostic factors. 1986

L Tran, and A Sadeghi, and D Hanson, and G Juillard, and R Mackintosh, and T C Calcaterra, and R G Parker

A retrospective review of 133 patients with major salivary gland carcinomas treated between 1955 and 1981 is presented. The majority of cases (104) originated in the parotid gland. The most common histological type was mucoepidermoid carcinoma (39 cases). Tumor-free interval was longest for patients with acinic cell and mucoepidermoid carcinomas. In contrast, adenoid cystic carcinoma was poorly controlled, regardless of the form of treatment. Initial control of primary major salivary gland tumors was inversely related to the presence of disease at the surgical margins. In cases with microscopic or gross disease at the surgical margins, postoperative radiation therapy controlled the tumor locally in 18 of 26 patients (69%). Postoperative radiation therapy was generally used only in cases with high-grade histologies, advanced stages, or positive surgical margins. Of the patients treated with surgery alone, 53% achieved local control, as compared to 75% of the group which received postoperative radiation therapy. Although the difference was not statistically significant, we would have expected the combined therapy group to have a lower control rate due to more advanced disease. There was a low salvage rate (22%) and a high incidence of distant metastasis (60%) in recurrent cases. The data indicates that complete surgical resection results in the best local control, with or without adjuvant radiation. When the surgical margin is inadequate and re-excision not possible, adjuvant radiation therapy appears to have a role to optimize local control and survival.

UI MeSH Term Description Entries
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009361 Neoplasm Invasiveness Ability of neoplasms to infiltrate and actively destroy surrounding tissue. Invasiveness, Neoplasm,Neoplasm Invasion,Invasion, Neoplasm
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011879 Radiotherapy Dosage The total amount of radiation absorbed by tissues as a result of radiotherapy. Dosage, Radiotherapy,Dosages, Radiotherapy,Radiotherapy Dosages
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal

Related Publications

L Tran, and A Sadeghi, and D Hanson, and G Juillard, and R Mackintosh, and T C Calcaterra, and R G Parker
May 1991, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al],
L Tran, and A Sadeghi, and D Hanson, and G Juillard, and R Mackintosh, and T C Calcaterra, and R G Parker
August 2001, The Laryngoscope,
L Tran, and A Sadeghi, and D Hanson, and G Juillard, and R Mackintosh, and T C Calcaterra, and R G Parker
July 2017, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons,
L Tran, and A Sadeghi, and D Hanson, and G Juillard, and R Mackintosh, and T C Calcaterra, and R G Parker
December 1991, Cancer,
L Tran, and A Sadeghi, and D Hanson, and G Juillard, and R Mackintosh, and T C Calcaterra, and R G Parker
April 2021, Head & neck,
L Tran, and A Sadeghi, and D Hanson, and G Juillard, and R Mackintosh, and T C Calcaterra, and R G Parker
September 2023, Oral oncology,
L Tran, and A Sadeghi, and D Hanson, and G Juillard, and R Mackintosh, and T C Calcaterra, and R G Parker
May 2010, Critical reviews in oncology/hematology,
L Tran, and A Sadeghi, and D Hanson, and G Juillard, and R Mackintosh, and T C Calcaterra, and R G Parker
January 1959, A.M.A. archives of surgery,
L Tran, and A Sadeghi, and D Hanson, and G Juillard, and R Mackintosh, and T C Calcaterra, and R G Parker
January 1998, Acta oncologica (Stockholm, Sweden),
L Tran, and A Sadeghi, and D Hanson, and G Juillard, and R Mackintosh, and T C Calcaterra, and R G Parker
March 2016, Oral oncology,
Copied contents to your clipboard!